QT
PACB icon

Quantamental Technologies’s Pacific Biosciences PACB Stock Holding History

Quantamental Technologies’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7,384
Closed -$53K – 1714
2019
Q1 		$53K Buy
+7,384
New +$53.4K 0.02% 847

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

Quantamental Technologies's PACB Position: Q2 2019 in Review

Quantamental Technologies sold out of Pacific Biosciences (PACB) in Q2 2019, closing a stake of 7,384 shares — an estimated $53K sold.

Quantamental Technologies first reported a position in PACB in Q1 2019 and held it in 1 quarter. The position peaked at $53K in Q1 2019. 150 funds tracked by Wall St. Rank hold PACB as of Q2 2019.

  • Quantamental Technologies reported no remaining Pacific Biosciences position as of Q2 2019 after selling out during the quarter.
  • Quantamental Technologies sold 7,384 Pacific Biosciences shares in Q2 2019, an estimated $53K.
  • Quantamental Technologies first reported a position in Pacific Biosciences in Q1 2019 and held it in 1 quarter.
  • Quantamental Technologies's Pacific Biosciences position peaked at $53K in Q1 2019.
  • 150 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2019.

Based on Quantamental Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.